[{"id":"65969d8a-b172-4873-a916-4494ff06814d","acronym":"IMA401-101","url":"https://clinicaltrials.gov/study/NCT05359445","created_at":"2022-05-03T14:54:12.020Z","updated_at":"2025-02-25T17:37:48.710Z","phase":"Phase 1","brief_title":"IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor","source_id_and_acronym":"NCT05359445 - IMA401-101","lead_sponsor":"Immatics Biotechnologies GmbH","biomarkers":" MAGEA4","pipe":" | ","alterations":" MAGEA4 expression • MAGEA4 overexpression","tags":["MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MAGEA4 expression • MAGEA4 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • IMA401"],"overall_status":"Recruiting","enrollment":" Enrollment 95","initiation":"Initiation: 05/19/2022","start_date":" 05/19/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 12/01/2029","study_completion_date":" 12/01/2029","last_update_posted":"2025-01-28"},{"id":"269bcf7a-a222-4eb1-a733-a5c181aede05","acronym":"SURPASS-3","url":"https://clinicaltrials.gov/study/NCT05601752","created_at":"2022-11-05T15:14:24.529Z","updated_at":"2024-07-02T16:34:25.911Z","phase":"Phase 2","brief_title":"ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)","source_id_and_acronym":"NCT05601752 - SURPASS-3","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • BRCA • PARP1 • MAGEA4","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • BRCA • PARP1 • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • BRCA mutation • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 08/12/2026","primary_completion_date":" 08/12/2026","study_txt":" Completion: 08/12/2026","study_completion_date":" 08/12/2026","last_update_posted":"2024-06-14"},{"id":"81497553-3d5a-49ef-8513-cf9cb5b29947","acronym":"","url":"https://clinicaltrials.gov/study/NCT05642455","created_at":"2022-12-08T14:57:33.766Z","updated_at":"2024-07-02T16:35:07.743Z","phase":"Phase 1/2","brief_title":"SPEARHEAD-3 Pediatric Study","source_id_and_acronym":"NCT05642455","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 07/30/2038","study_completion_date":" 07/30/2038","last_update_posted":"2024-04-24"},{"id":"2c13cc26-0e5f-458f-80db-772216b113f8","acronym":"SPEARHEAD-1","url":"https://clinicaltrials.gov/study/NCT04044768","created_at":"2021-01-18T19:50:39.967Z","updated_at":"2024-07-02T16:35:18.934Z","phase":"Phase 2","brief_title":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT04044768 - SPEARHEAD-1","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/13/2019","start_date":" 08/13/2019","primary_txt":" Primary completion: 10/10/2021","primary_completion_date":" 10/10/2021","study_txt":" Completion: 04/01/2038","study_completion_date":" 04/01/2038","last_update_posted":"2024-02-19"},{"id":"fc2b490f-716a-4fb8-8ba2-7e656cf95939","acronym":"SURPASS","url":"https://clinicaltrials.gov/study/NCT04044859","created_at":"2021-01-18T19:50:41.997Z","updated_at":"2024-07-02T16:35:19.014Z","phase":"Phase 1","brief_title":"ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)","source_id_and_acronym":"NCT04044859 - SURPASS","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecelra (afamitresgene autoleucel) • uzatresgene autoleucel (ADP-A2M4CD8)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 08/20/2019","start_date":" 08/20/2019","primary_txt":" Primary completion: 12/23/2025","primary_completion_date":" 12/23/2025","study_txt":" Completion: 04/30/2037","study_completion_date":" 04/30/2037","last_update_posted":"2024-02-16"},{"id":"4317ceb2-4fba-4c3e-9e3a-12523bffaa99","acronym":"","url":"https://clinicaltrials.gov/study/NCT03132922","created_at":"2021-01-18T15:26:11.009Z","updated_at":"2024-07-02T16:35:22.736Z","phase":"Phase 1","brief_title":"MAGE-A4ᶜ¹º³²T for Multi-Tumor","source_id_and_acronym":"NCT03132922","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecelra (afamitresgene autoleucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 12/27/2022","primary_completion_date":" 12/27/2022","study_txt":" Completion: 09/01/2032","study_completion_date":" 09/01/2032","last_update_posted":"2024-01-22"},{"id":"d41013a9-659b-4bd4-843d-44f12482f427","acronym":"STELLA","url":"https://clinicaltrials.gov/study/NCT02475707","created_at":"2021-01-18T11:55:12.467Z","updated_at":"2024-07-02T16:35:31.622Z","phase":"Phase 1","brief_title":"Administration of Donor MultiTAA-Specific T Cells for ALL","source_id_and_acronym":"NCT02475707 - STELLA","lead_sponsor":"Baylor College of Medicine","biomarkers":" CD8 • CD4 • MME","pipe":"","alterations":" ","tags":["CD8 • CD4 • MME"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 10/29/2019","primary_completion_date":" 10/29/2019","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2023-10-26"},{"id":"4c345493-ab62-410a-b773-a42c655f0249","acronym":"PDC-LUNG-101","url":"https://clinicaltrials.gov/study/NCT03970746","created_at":"2021-01-18T19:31:48.798Z","updated_at":"2024-07-02T16:35:31.964Z","phase":"Phase 1/2","brief_title":"Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC","source_id_and_acronym":"NCT03970746 - PDC-LUNG-101","lead_sponsor":"PDC*line Pharma SAS","biomarkers":" CD8 • HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["CD8 • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • pemetrexed • PDC*lung"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 73","initiation":"Initiation: 09/10/2019","start_date":" 09/10/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-24"},{"id":"9eac4268-8e45-4c25-be18-2972151ca188","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494167","created_at":"2021-01-18T12:01:22.240Z","updated_at":"2024-07-02T16:35:45.346Z","phase":"Phase 1","brief_title":"Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)","source_id_and_acronym":"NCT02494167","lead_sponsor":"Baylor College of Medicine","biomarkers":" KIT • WT1 • CD33 • ANPEP","pipe":"","alterations":" ","tags":["KIT • WT1 • CD33 • ANPEP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MultiTAA T cell therapy"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 04/01/2024","primary_completion_date":" 04/01/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-06-19"},{"id":"6cdd3bab-2dd1-4a70-9cc4-0b496a44b196","acronym":"KSH01-TCRT","url":"https://clinicaltrials.gov/study/NCT05539833","created_at":"2022-09-14T18:56:19.768Z","updated_at":"2024-07-02T16:35:51.604Z","phase":"Phase 1","brief_title":"KSH01-TCRT Solid Tumors","source_id_and_acronym":"NCT05539833 - KSH01-TCRT","lead_sponsor":"TCRx Therapeutics Co.Ltd","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KSH01"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/19/2022","start_date":" 08/19/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2027","study_completion_date":" 07/31/2027","last_update_posted":"2023-04-03"},{"id":"e1041808-e70d-49d7-83f7-a1e19c798274","acronym":" SPEARHEAD-2","url":"https://clinicaltrials.gov/study/NCT04408898","created_at":"2021-01-18T21:15:39.069Z","updated_at":"2024-07-02T16:36:20.662Z","phase":"Phase 2","brief_title":"SPEARHEAD 2 Study in Subjects With Recurrent or Metastatic Head and Neck Cancer","source_id_and_acronym":"NCT04408898 -  SPEARHEAD-2","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • MAGEA4","pipe":" | ","alterations":" HLA-A*02 • HLA-A2 positive • MAGEA4 expression","tags":["HLA-A • MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A2 positive • MAGEA4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tecelra (afamitresgene autoleucel)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/02/2020","start_date":" 07/02/2020","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-11-16"},{"id":"65ccaf9d-1aaa-48e3-98b4-14d4e6be1110","acronym":"","url":"https://clinicaltrials.gov/study/NCT02096614","created_at":"2021-01-18T09:40:44.722Z","updated_at":"2024-07-02T16:36:28.955Z","phase":"Phase 1","brief_title":"Investigator Initiated Phase 1 Study of TBI-1201","source_id_and_acronym":"NCT02096614","lead_sponsor":"Mie University","biomarkers":" MAGEA4","pipe":" | ","alterations":" MAGEA4 expression • HLA-A*24","tags":["MAGEA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MAGEA4 expression • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TBI 1201 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 04/01/2014","start_date":" 04/01/2014","primary_txt":" Primary completion: 03/01/2021","primary_completion_date":" 03/01/2021","study_txt":" Completion: 03/01/2021","study_completion_date":" 03/01/2021","last_update_posted":"2021-06-18"}]